4.3 Article

Intravenous flurbiprofen for post-thymectomy pain relief in patients with myasthenia gravis

期刊

出版社

BIOMED CENTRAL LTD
DOI: 10.1186/1749-8090-7-98

关键词

Myasthenia gravis; Thymectomy; Postoperative care

向作者/读者索取更多资源

Background: Post-thymectomy pain in myasthenia gravis (MG) patients can inhibit breathing and coughing. Inappropriate usage of analgesics may exacerbate respiratory inhibition and even cause myasthenic crisis. Flurbiprofen is a non-steroidal anti-inflammatory drug (NSAID) that is commonly used to control moderate postoperative pain and is not associated with respiratory inhibition. We hypothesized that flurbiprofen may provide post-thymectomy pain relief without increasing the risk of complications in MG patients. Methods: Two hundred MG patients underwent extended thymectomy from March 2006 to December 2010 and were randomly allocated to a flurbiprofen group (110 patients, 50 mg intravenous flurbiprofen axetil) or a control group (90 patients, 100 mg intramuscular tramadol) as postoperative analgesia. Visual analog scale (VAS) pain score, heart rate, blood pressure, respiratory rate, pulse oximetry (SpO(2)), and adverse effects were recorded before and up to 24 h after drug administration. Results: There were no significant differences in the preoperative clinical characteristics of the flurbiprofen and control (tramadol) groups. Both flurbiprofen and tramadol significantly alleviated post-thymectomy pain (p < 0.05 for both), but patients in flurbiprofen group had significantly lower VAS pain scores at 0.5 h, 2 h, 4 h, and 8 h after surgery (p < 0.05 for all times). There were no significant post-thymectomy changes of heart rate, respiratory rate, mean arterial blood pressure, or SpO(2) in either group at all time points. Conclusions: Post-thymectomy intravenous administration of flurbiprofen axetil provides safe and effective analgesia for MG patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Immunology

Imbalance in T follicular helper cells producing IL-17 promotes pro-inflammatory responses in MuSK antibody positive myasthenia gravis

Yingkai Li, Jeffrey T. Guptill, Melissa A. Russo, James F. Howard, Janice M. Massey, Vern C. Juel, Lisa D. Hobson-Webb, Doug Emmett, Manisha Chopra, Shruti Raja, Weibin Liu, John S. Yi

JOURNAL OF NEUROIMMUNOLOGY (2020)

Review Clinical Neurology

AChR myasthenia gravis switching to MuSK or double antibody positive myasthenia gravis in two children and literature review

Yaru Lu, Hao Ran, Wenhao Yang, Qian Ma, Li Qiu, Changyi Ou, Pei Chen, Zhongqiang Lin, Weibin Liu

NEUROMUSCULAR DISORDERS (2020)

Article Clinical Neurology

Thymomatous myasthenia gravis: 10-year experience of a single center

Jiaxin Chen, Wenjin Shang, Yin Chen, Yan Li, Xin Huang, Chunhua Su, Kai Zhu, Jieni Zhang, Weibin Liu, Huiyu Feng

Summary: Thymomatous myasthenia gravis (T-MG) differs clinically from non-thymomatous myasthenia gravis (NT-MG), with thymoma considered a risk factor for MG. Preoperative use of anticholinesterase drugs is a protective factor for the long-term prognosis of T-MG. Understanding the characteristics of T-MG may help improve its prognosis.

ACTA NEUROLOGICA SCANDINAVICA (2021)

Article Immunology

Quantitative features and clinical significance of two subpopulations of AChR-specific CD4+T cells in patients with myasthenia gravis

Xiaoxi Liu, Qian Ma, Li Qiu, Changyi Ou, Zhongqiang Lin, Yaru Lu, Huan Huang, Pei Chen, Zhidong Huang, Weibin Liu

CLINICAL IMMUNOLOGY (2020)

Article Biochemistry & Molecular Biology

Oleophylic Nanospheres Self-Assembly by Emulsion Technique Utilizing the Automatic Nanoscalar Interfacial Alternation (ANIAE)

Hao Ran, Weibin Liu, Xin Pan, Chuanbin Wu, Guilan Quan, Ying Huang, Yingtong Cui

Summary: This study presents a multifunctional approach for pharmaceutical management, utilizing the ANIAE technique to assemble nanospheres in one step using polyprotein microspheres. The results demonstrate a versatile and universal solution for insoluble active ingredients.

CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2021)

Article Immunology

Circulating Th1/17 cells serve as a biomarker of disease severity and a target for early intervention in AChR-MG patients

Qian Ma, Hao Ran, Yingkai Li, Yaru Lu, Xiaoxi Liu, Huan Huang, Wenhao Yang, Lu Yu, Pei Chen, Xin Huang, Li Qiu, Zhongqiang Lin, Changyi Ou, Weibin Liu

CLINICAL IMMUNOLOGY (2020)

Review Clinical Neurology

AChRAb and MuSKAb double-seropositive myasthenia gravis: a distinct subtype?

Jieni Zhang, Yin Chen, Jiaxin Chen, Xin Huang, Haiyan Wang, Yan Li, Weibin Liu, Huiyu Feng

Summary: The study found that DSP-MG in southern China has more severe symptoms and poor prognosis compared to AChR-MG, with no significant differences compared to MuSK-MG. The researchers speculated that DSP-MG may be a subtype of MuSK-MG.

NEUROLOGICAL SCIENCES (2021)

Article Immunology

Leflunomide ameliorates experimental autoimmune myasthenia gravis by regulating humoral and cellular immune responses

Huan Huang, Hao Ran, Xiaoxi Liu, Lu Yu, Li Qiu, Zhongqiang Lin, Changyi Ou, Yaru Lu, Wenhao Yang, Weibin Liu

Summary: The study found that leflunomide can alleviate the severity of EAMG by regulating humoral immune responses and balancing Th cell subsets, potentially by inhibiting Tfh cells and reducing antibody secretion.

INTERNATIONAL IMMUNOPHARMACOLOGY (2021)

Article Clinical Neurology

Status of Immunotherapy Acceptance in Chinese Patients With Multiple Sclerosis: Analysis of Multiple Sclerosis Patient Survival Report 2018

Ran Zhou, Qiuming Zeng, Huan Yang, Yan Xu, Guojun Tan, Hongbo Liu, Lihua Wang, Hongyu Zhou, Meini Zhang, Jinzhou Feng, Tao Jin, Xinghu Zhang, Jiawei Wang, Xu Zhang, Feng Gao, Chunsheng Yang, Bitao Bu, Chunyang Li, Min Zhang, Huiqing Dong, Aiyu Lin, Weibin Liu, Lei Wu, Manxia Wang, Yulan Tang, Honghao Wang, Youming Long, Zhe Wang, Weihong Zheng

Summary: The study found that highly educated patients with frequent relapses were more willing to receive treatment, while patients with more understanding of the disease opted to be treated. Younger patients, those with severe disease course, and those with more symptoms were more likely to choose treatment. A higher proportion of women chose to be treated with DMTs than with other immunotherapies.

FRONTIERS IN NEUROLOGY (2021)

Article Clinical Neurology

Clinical evaluation of efficacy of leflunomide combined with low-dose prednisone for treatment of myasthenia gravis

Xin Huang, Li Qiu, Yaru Lu, Jiaxin Chen, Wenhao Yang, Changyi Ou, Hao Ran, Weibin Liu

Summary: The combination therapy of leflunomide and low-dose prednisone has been shown to be clinically effective in treating myasthenia gravis (MG), improving patients' clinical symptoms and having a promising treatment effect, especially for generalized MG.

ACTA NEUROLOGICA BELGICA (2023)

Review Clinical Neurology

Is myasthenia gravis a contraindication for botulinum toxin?

Qian Ma, Hao Ran, Changyi Ou, Xiaoxi Liu, Yaru Lu, Huan Huang, Wenhao Yang, Lu Yu, Pei Chen, Xin Huang, Li Qiu, Zhongqiang Lin, Zhidong Huang, Weibin Liu

Summary: Based on clinical data and literature review, it was found that under proper management, patients with myasthenia gravis (MG) can safely and successfully use botulinum toxin (BTX) for comorbidities.

JOURNAL OF CLINICAL NEUROSCIENCE (2022)

Article Geriatrics & Gerontology

Quantification of dendritic cell subsets in human thymus tissues of various ages

Yan Li, Pei Chen, Hao Huang, Huiyu Feng, Hao Ran, Weibin Liu

Summary: This study found that all common DC subsets are present in the human thymus of various ages, with the density of pDCs gradually increasing with age, suggesting an additional role of pDCs in the thymus beyond central tolerance. The ratio of medulla to cortex area in the human thymus increases with age, while the densities of different DC subsets also show changes.

IMMUNITY & AGEING (2021)

Article Psychiatry

Studying the relationship between clinical features and mental health among late-onset myasthenia gravis patients

Lu Yu, Li Qiu, Hao Ran, Qian Ma, Ya-Ru Lu, Wei-Bin Liu

Summary: Late-onset myasthenia gravis (MG) patients, especially women, are more likely to experience anxiety and depression, with higher MG-QOL-15 scores correlating with increased incidence.

WORLD JOURNAL OF PSYCHIATRY (2022)

Article Clinical Neurology

Leflunomide combined with low-dose prednisone inhibits proinflammatory T cells responses in myasthenia gravis patients

Xin Huang, Hao Ran, Yingkia Li, Qian Ma, Changyi Ou, Li Qiu, Huiyu Feng, Weibin Liu

Summary: The combination of leflunomide and low-dose prednisone can significantly reduce the frequency of Th1 and Th17 cells, as well as the secretion of pro-inflammatory cytokines IL-17 and IL-9, thereby improving the clinical symptoms of myasthenia gravis (MG).

FRONTIERS IN NEUROLOGY (2022)

Article Neurosciences

Immunotherapy choice and maintenance for generalized myasthenia gravis in China

Chao Zhang, Bitao Bu, Huan Yang, Lihua Wang, Weibin Liu, Rui-Sheng Duan, Meini Zhang, Pei Zeng, Chen Du, Li Yang, Fu-Dong Shi

CNS NEUROSCIENCE & THERAPEUTICS (2020)

暂无数据